Stryker, analyst consensus stays constructive, shares trade near recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 10:31.

Stryker Corp. (US8636671013) starts this Tuesday with a steady view from Wall Street, where the stock trades on the NYSE and remains a core name in US medical technology portfolios. The focus today is on the analyst consensus that continues to describe the shares as a solid long-term healthcare holding.

How analysts view Stryker

Major US and international research houses have followed Stryker for years and typically maintain either Buy or Hold ratings, reflecting the company’s established position in orthopedic implants and surgical equipment. Several large brokers in New York and London point to consistent organic growth and a history of disciplined acquisitions in medical devices when justifying their stance.

On typical consensus screens the majority of covering analysts cluster on the positive side, with only a handful of more cautious voices highlighting valuation after a strong multi-year run. The spread of views gives retail investors a relatively clear picture: Stryker is seen as a quality name in the sector, but one where expectations on margins and cash generation must be met to support the current price levels.

What the numbers usually show

In recent reporting cycles Stryker has tended to post mid-single to low-double-digit revenue growth, driven by hip and knee replacements, trauma products and surgical technologies for hospitals worldwide. Earnings per share have broadly tracked this top-line expansion, helped by scale effects and ongoing efficiency programs in manufacturing and logistics.

Analysts often highlight Stryker’s ability to convert earnings into cash, which underpins regular investment in research and development and selective bolt-on deals in adjacent medical technology niches. For many houses this operational profile justifies a valuation premium versus more cyclical industrial names, even though healthcare spending is subject to budget discussions in the US and other key markets.

How Stryker makes its money

Stryker generates most of its revenue with orthopedic implants, trauma and extremities products, and a growing range of surgical equipment for operating rooms. The portfolio spans joint replacement systems, spine and neurotechnology devices, power tools for surgeons and patient handling equipment for hospitals and care facilities.

Where the stock trades today

The Stryker shares (US8636671013) trade on 2026-06-30, 10:31 on the NYSE in US dollars, reflecting the company’s position as a US large-cap healthcare name.

This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Historical figures and consensus data are indicative and may change without notice.